A Study of Ivonescimab in Combination With DatoDXd or Osimertinib in People With Non-Small Cell Lung Cancer

Full Title

A Phase 1/2 Trial of Ivonescimab with Dato-DXd or Osimertinib in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer that Progressed on EGFR TKI Therapy

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Helena Yu’s office at 646-608-3912.

Protocol
25-366
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Helena A. Yu
Co-Investigators
Gregory J. Riely
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07535437
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description